This document id is 30160001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160001 </arg2>	0.9999751448631287
Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .	<arg1> Tumors in the head region </arg1> <rel> include </rel> <arg2> a heterogeneous group of carcinomas whose treatment has advanced in recent years </arg2>	0.9860756993293762
Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .	<arg1> a heterogeneous group of carcinomas </arg1> <rel> has advanced </rel> <arg2> in recent years </arg2>	0.8968717455863953
Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .	<arg1> Tumors in the neck region </arg1> <rel> include </rel> <arg2> a heterogeneous group of carcinomas whose treatment has advanced in recent years </arg2>	0.9862416982650757
This document id is 30160002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160002 </arg2>	0.9999750852584839
Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .	<arg1> Tumors in the head region </arg1> <rel> comprise </rel> <arg2> a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years </arg2>	0.9998730421066284
Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .	<arg1> heterogeneous group carcinomas therapy progress </arg1> <rel> has been observed </rel> <arg2> in recent years </arg2>	0.45496898889541626
Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .	<arg1> Tumors in the neck region </arg1> <rel> comprise </rel> <arg2> a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years </arg2>	0.9998734593391418
Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .	<arg1> carcinomas progress </arg1> <rel> has been observed </rel> <arg2> in recent years </arg2>	0.4685906767845154
This document id is 30160011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160011 </arg2>	0.999977171421051
This document id is 30160012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160012 </arg2>	0.9999765753746033
This document id is 30160021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160021 </arg2>	0.9999738335609436
This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .	<arg1> This shift </arg1> <rel> changes </rel> <arg2> the understanding of the disease </arg2>	0.9999911785125732
This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .	<arg1> This shift </arg1> <rel> changes </rel> <arg2> its therapy </arg2>	0.999993085861206
This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .	<arg1> This shift </arg1> <rel> changes </rel> <arg2> the life expectancy of those </arg2>	0.9998959898948669
This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .	<arg1> those </arg1> <rel> affected </rel> <arg2>  </arg2>	0.9997265934944153
This document id is 30160022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160022 </arg2>	0.9999778270721436
This changes the understanding of the disease , its therapy and the life expectancy of those affected .	<arg1> This </arg1> <rel> changes </rel> <arg2> the understanding of the disease </arg2>	0.9999877214431763
This changes the understanding of the disease , its therapy and the life expectancy of those affected .	<arg1> This </arg1> <rel> changes </rel> <arg2> its therapy </arg2>	0.9999902248382568
This changes the understanding of the disease , its therapy and the life expectancy of those affected .	<arg1> This </arg1> <rel> changes </rel> <arg2> the life expectancy of those </arg2>	0.9999126195907593
This changes the understanding of the disease , its therapy and the life expectancy of those affected .	<arg1> those </arg1> <rel> affected </rel> <arg2>  </arg2>	0.9998273253440857
This document id is 30160031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160031 </arg2>	0.9999797344207764
This work focuses on radiation therapy , a treatment option with possible short- and long-term complications , and the resulting consequences for the patients ' quality of life .	<arg1> This work </arg1> <rel> focuses </rel> <arg2> on the resulting consequences for the patients ' quality of life </arg2>	0.9999776482582092
This work focuses on radiation therapy , a treatment option with possible short- and long-term complications , and the resulting consequences for the patients ' quality of life .	<arg1> This work </arg1> <rel> focuses </rel> <arg2> on radiation therapy </arg2>	0.9999933242797852
This document id is 30160032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160032 </arg2>	0.9999775290489197
The focus here will be on radiation treatment , a treatment option with potential short- and long-term complications and the resulting consequences for patients ' quality of life .	<arg1> The focus here </arg1> <rel> will be </rel> <arg2> on radiation treatment </arg2>	0.9999843239784241
This document id is 30160041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160041 </arg2>	0.9999799728393555
Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .	<arg1> we </arg1> <rel> show </rel> <arg2> which supportive measures can be taken during radiation therapy with the help of clinical pharmacists </arg2>	0.9999369382858276
Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .	<arg1> which supportive measures </arg1> <rel> can be taken </rel> <arg2> during radiation therapy with the help of clinical pharmacists </arg2>	0.9276491403579712
Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .	<arg1> we </arg1> <rel> show </rel> <arg2> which supportive measures can be taken after radiation therapy with the help of clinical pharmacists </arg2>	0.9999448657035828
Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .	<arg1> which supportive measures </arg1> <rel> can be taken </rel> <arg2> after radiation therapy with the help of clinical pharmacists </arg2>	0.8699398636817932
This document id is 30160042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30160042 </arg2>	0.9999783635139465
Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists .	<arg1> it </arg1> <rel> will be shown </rel> <arg2>  </arg2>	0.999896764755249
Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists .	<arg1> which supportive measures </arg1> <rel> can be taken </rel> <arg2> during radiation treatment with the participation of clinical pharmacists </arg2>	0.14670391380786896
Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists .	<arg1> which supportive measures </arg1> <rel> can be taken </rel> <arg2> after radiation treatment with the participation of clinical pharmacists </arg2>	0.18820510804653168
This document id is 30170001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170001 </arg2>	0.9999813437461853
Daunorubicin has been established as important cornerstone in ALL- and AML-treatment since many years .	<arg1> Daunorubicin </arg1> <rel> has been established </rel> <arg2> as important cornerstone in ALL- and AML-treatment since many years </arg2>	0.9998601675033569
This document id is 30170002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170002 </arg2>	0.999981164932251
The anthracycline daunorubicin has been an integral part of ALL and AML treatment for many years .	<arg1> The anthracycline daunorubicin </arg1> <rel> has been </rel> <arg2> an integral part of ALL treatment for many years </arg2>	0.9981986880302429
The anthracycline daunorubicin has been an integral part of ALL and AML treatment for many years .	<arg1> The anthracycline daunorubicin </arg1> <rel> has been </rel> <arg2> an integral part of AML treatment for many years </arg2>	0.9979888796806335
This document id is 30170011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170011 </arg2>	0.9999829530715942
Its metabolite daunorubicinol does not contribute to antineoplastic activities of the anthracycline , however , it may have a potential impact on drug 's cardiotoxicity .	<arg1> it </arg1> <rel> may have </rel> <arg2> a potential impact on drug 's cardiotoxicity </arg2>	0.9991877675056458
Its metabolite daunorubicinol does not contribute to antineoplastic activities of the anthracycline , however , it may have a potential impact on drug 's cardiotoxicity .	<arg1> Its metabolite daunorubicinol </arg1> <rel> does not contribute </rel> <arg2> to antineoplastic activities of the anthracycline </arg2>	0.9986152052879333
This document id is 30170012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170012 </arg2>	0.9999827742576599
The metabolite daunorubicinol plays less of a role in the antineoplastic effect , but probably more in the potential cardiotoxicity of the cytostatic .	<arg1> The metabolite daunorubicinol </arg1> <rel> plays </rel> <arg2> less of a role in the antineoplastic effect </arg2>	0.997742235660553
The metabolite daunorubicinol plays less of a role in the antineoplastic effect , but probably more in the potential cardiotoxicity of the cytostatic .	<arg1> The metabolite daunorubicinol </arg1> <rel> plays </rel> <arg2> more in the potential cardiotoxicity of the cytostatic </arg2>	0.9685313105583191
This document id is 30170021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170021 </arg2>	0.9999804496765137
Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .	<arg1> Current guidelines in Germany </arg1> <rel> consider </rel> <arg2> a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min </arg2>	0.9995048642158508
Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .	<arg1> 30 and 50 ml/min </arg1> <rel> is </rel> <arg2> in contrast to FDA-based guidelines </arg2>	0.9976592659950256
Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .	<arg1> 30 and 50 ml/min </arg1> <rel> is </rel> <arg2> somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin are compared with each other </arg2>	0.9225844144821167
Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .	<arg1> the clinical pharmacokinetic behaviour of daunorubicin </arg1> <rel> are compared </rel> <arg2> with each other </arg2>	0.9970914125442505
Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .	<arg1> 30 and 50 ml/min </arg1> <rel> is </rel> <arg2> somewhat confusing when the clinical pharmacokinetic behaviour of doxorubicin are compared with each other </arg2>	0.9114661812782288
Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .	<arg1> the clinical pharmacokinetic behaviour of doxorubicin </arg1> <rel> are compared </rel> <arg2> with each other </arg2>	0.9978411197662354
This document id is 30170022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170022 </arg2>	0.9999829530715942
The currently filed guidelines for dose modification stipulate that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min .	<arg1> The currently filed guidelines for dose modification </arg1> <rel> stipulate </rel> <arg2> that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min </arg2>	0.9922170042991638
The currently filed guidelines for dose modification stipulate that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min .	<arg1> the anthracycline </arg1> <rel> should only be used </rel> <arg2> at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min </arg2>	0.9660460948944092
This document id is 30170031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170031 </arg2>	0.999984085559845
As a consequence , a leukemia patient may receive daunorubicin full dose in the US , and 50 % of curative dose in Germany in case of e.g . GFR 43 ml/min .	<arg1> a leukemia patient </arg1> <rel> may receive </rel> <arg2> daunorubicin full dose in the US </arg2>	0.9487054347991943
As a consequence , a leukemia patient may receive daunorubicin full dose in the US , and 50 % of curative dose in Germany in case of e.g . GFR 43 ml/min .	<arg1> a leukemia patient </arg1> <rel> may 50 </rel> <arg2> % of curative dose in Germany in case of . GFR 43 e.g ml/min </arg2>	0.5143402218818665
This document id is 30170032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170032 </arg2>	0.9999825954437256
This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .	<arg1> This requirement </arg1> <rel> is </rel> <arg2> irritating </arg2>	0.9998980760574341
This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .	<arg1> This requirement </arg1> <rel> considering </rel> <arg2> that ( 1 ) the FDA has not provided a corresponding recommendation to date </arg2>	0.1408490091562271
This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .	<arg1> the FDA </arg1> <rel> has not provided </rel> <arg2> a corresponding recommendation to date </arg2>	0.9770628809928894
This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .	<arg1> This requirement </arg1> <rel> considering </rel> <arg2> that ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin </arg2>	0.999764621257782
This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .	<arg1> ( 2 ) recent work </arg1> <rel> has identified </rel> <arg2> very large clinical pharmacokinetic parallels between daunorubicin </arg2>	0.9336882829666138
This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .	<arg1> This requirement </arg1> <rel> considering </rel> <arg2> that ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between doxorubicin </arg2>	0.9997463226318359
This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .	<arg1> ( 2 ) recent work </arg1> <rel> has identified </rel> <arg2> very large clinical pharmacokinetic parallels between doxorubicin </arg2>	0.9332197308540344
This document id is 30170041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170041 </arg2>	0.9999839067459106
Thus , a revised assessment of current guidelines on a regulatory level is of great interest for clinical oncologist .	<arg1> a revised assessment of current guidelines on a regulatory level </arg1> <rel> is </rel> <arg2> of great interest for clinical oncologist </arg2>	0.9999340772628784
This document id is 30170042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170042 </arg2>	0.9999830722808838
Thus , a leukemia patient with a GFR of 43 ml/min would receive only 50 % of the curatively scheduled dose in Germany compared with the United States .	<arg1> a leukemia patient with a GFR of 43 ml/min </arg1> <rel> would receive </rel> <arg2> only 50 % of the curatively scheduled dose in Germany compared States </arg2>	0.6873780488967896
This document id is 30170052 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30170052 </arg2>	0.9999788999557495
A timely regulatory reassessment of this issue is therefore of great clinical oncological interest .	<arg1> A timely regulatory reassessment of this issue </arg1> <rel> is therefore </rel> <arg2> of great clinical oncological interest </arg2>	0.9822570085525513
This document id is 30180001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180001 </arg2>	0.9999738335609436
Vancomycin ( VAN ) is an established treatment option for infections involving methicillin-resistant Staphylococcus aureus strains ( MRSA ) .	<arg1> Vancomycin </arg1> <rel> is </rel> <arg2> an established treatment option for infections </arg2>	0.9999446868896484
Vancomycin ( VAN ) is an established treatment option for infections involving methicillin-resistant Staphylococcus aureus strains ( MRSA ) .	<arg1> infections </arg1> <rel> involving </rel> <arg2> methicillin-resistant Staphylococcus aureus strains </arg2>	0.9997378587722778
This document id is 30180002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180002 </arg2>	0.9999667406082153
Vancomycin ( VAN ) is an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains .	<arg1> Vancomycin </arg1> <rel> is </rel> <arg2> an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains </arg2>	0.9998947978019714
This document id is 30180011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180011 </arg2>	0.9999698996543884
However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .	<arg1> the bactericidal effect of VAN on MRSA both </arg1> <rel> is reduced </rel> <arg2> strains inhibitory ( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure the `` range to < through levels </arg2>	0.05841126665472984
However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .	<arg1> both EUCAST Conversely the clinical medical societies </arg1> <rel> reduced increased </rel> <arg2> the `` sensitive '' MIC range to < 2 mg/L the target ranges of VAN plasma </arg2>	0.1423506736755371
However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .	<arg1> . the clinical medical societies the target </arg1> <rel> ranges </rel> <arg2> of VAN plasma through levels </arg2>	0.19852215051651
However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .	<arg1> the target </arg1> <rel> increased </rel> <arg2> of VAN plasma through levels </arg2>	0.32988664507865906
However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .	<arg1> the bactericidal effect of VAN on MRSA societies </arg1> <rel> is reduced </rel> <arg2> ( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure VAN plasma through levels </arg2>	0.13958674669265747
However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .	<arg1> both CLSI Conversely the clinical medical societies </arg1> <rel> reduced increased </rel> <arg2> the `` sensitive '' MIC range to < 2 mg/L the target ranges of </arg2>	0.24939469993114471
However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .	<arg1> mg/L the target </arg1> <rel> increased </rel> <arg2> of VAN plasma through levels </arg2>	0.24345503747463226
This document id is 30180012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180012 </arg2>	0.9999691247940063
However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .	<arg1> the bactericidal effect of VAN on MRSA </arg1> <rel> is reduced </rel> <arg2> for strains already </arg2>	0.9028849601745605
However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .	<arg1> the MIC of VAN </arg1> <rel> increases </rel> <arg2> to ≥1 mg/l </arg2>	0.9519516825675964
However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .	<arg1> CLSI </arg1> <rel> reduced </rel> <arg2> the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l </arg2>	0.27761590480804443
However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .	<arg1> clinical societies </arg1> <rel> increased </rel> <arg2> the target ranges for plasma levels </arg2>	0.001934914500452578
However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .	<arg1> the target </arg1> <rel> ranges </rel> <arg2> for plasma levels </arg2>	0.9502494931221008
However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .	<arg1> strains the MIC of VAN </arg1> <rel> increases </rel> <arg2> to ≥1 mg/l </arg2>	0.954696774482727
However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .	<arg1> EUCAST </arg1> <rel> is a correlation between the MIC and the risk of treatment failure of </rel> <arg2>  </arg2>	0.035652559250593185
This document id is 30180021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180021 </arg2>	0.9999659061431885
However , nephrotoxic and ototoxic effects limit the use of increased VAN dosages for the improvement of treatment efficacy .	<arg1> nephrotoxic effects </arg1> <rel> limit </rel> <arg2> the use of increased VAN dosages for the improvement of treatment efficacy </arg2>	0.9999496936798096
However , nephrotoxic and ototoxic effects limit the use of increased VAN dosages for the improvement of treatment efficacy .	<arg1> ototoxic effects </arg1> <rel> limit </rel> <arg2> the use of increased VAN dosages for the improvement of treatment efficacy </arg2>	0.9999455809593201
This document id is 30180022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180022 </arg2>	0.9999714493751526
However , nephro- and ototoxic effects limit VAN dose increases to improve therapy .	<arg1> nephro- effects </arg1> <rel> limit </rel> <arg2> VAN dose increases to improve therapy </arg2>	0.9779126048088074
However , nephro- and ototoxic effects limit VAN dose increases to improve therapy .	<arg1> ototoxic effects </arg1> <rel> limit </rel> <arg2> VAN dose increases to improve therapy </arg2>	0.9879671335220337
This document id is 30180031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180031 </arg2>	0.9999729990959167
Trough level monitoring and corresponding dose adjustments are recommended for the optimization of VAN exposure .	<arg1> Trough level monitoring </arg1> <rel> are recommended </rel> <arg2> for the optimization of VAN exposure </arg2>	0.9999831914901733
Trough level monitoring and corresponding dose adjustments are recommended for the optimization of VAN exposure .	<arg1> corresponding dose adjustments </arg1> <rel> are recommended </rel> <arg2> for the optimization of VAN exposure </arg2>	0.9999679923057556
This document id is 30180032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180032 </arg2>	0.9999707937240601
Valley level measurements after therapy initiation , with dose adjustment if necessary , are recommended to optimize VAN exposure .	<arg1> Valley level measurements after therapy initiation , with dose adjustment necessary </arg1> <rel> are recommended </rel> <arg2> to optimize VAN exposure </arg2>	0.9893518686294556
Valley level measurements after therapy initiation , with dose adjustment if necessary , are recommended to optimize VAN exposure .	<arg1> Valley level measurements after therapy initiation , with dose adjustment if necessary </arg1> <rel> to optimize </rel> <arg2> VAN exposure </arg2>	0.00023566666641272604
This document id is 30180041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180041 </arg2>	0.9999725222587585
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> we </arg1> <rel> investigated </rel> <arg2> the impact of dose regimens on the attainment of the newly defined target ranges until day 3 </arg2>	0.8096044063568115
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> the impact of dose regimens on the attainment of the newly defined target </arg1> <rel> ranges </rel> <arg2> until day 3 </arg2>	0.9872549176216125
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> we </arg1> <rel> investigated </rel> <arg2> the impact of dose regimens on the attainment of the newly defined target </arg2>	0.999772846698761
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> the impact of dose regimens on the attainment of the newly defined target </arg1> <rel> ranges </rel> <arg2> later in the course of treatment </arg2>	0.8980548977851868
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> we </arg1> <rel> investigated </rel> <arg2> the impact of patient characteristics on the attainment of the newly defined target ranges until day 3 </arg2>	0.9434093236923218
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> the impact of patient characteristics on the attainment of the newly defined target </arg1> <rel> ranges </rel> <arg2> until day 3 </arg2>	0.9570111632347107
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> we </arg1> <rel> investigated </rel> <arg2> the impact of patient characteristics on the attainment of the newly defined target ranges </arg2>	0.9328358173370361
Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .	<arg1> the impact of patient characteristics on the attainment of the newly defined target </arg1> <rel> ranges </rel> <arg2> later in the course of treatment </arg2>	0.7528629302978516
This document id is 30180042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180042 </arg2>	0.9999707937240601
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> we </arg1> <rel> retrospectively examined </rel> <arg2> the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by </arg2>	0.70754075050354
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> the influences of dosing regimens on the achievability of newly defined target </arg1> <rel> ranges </rel> <arg2> for VAN valley levels therapy day 3 by </arg2>	0.6450434327125549
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> we </arg1> <rel> retrospectively examined </rel> <arg2> the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by therapy day later </arg2>	0.5131655335426331
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> the influences of dosing regimens on the achievability of newly defined target </arg1> <rel> ranges </rel> <arg2> for VAN valley levels by therapy day later </arg2>	0.7319005131721497
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> we </arg1> <rel> retrospectively examined </rel> <arg2> the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 </arg2>	0.6965570449829102
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> the influences of patient characteristics on the achievability of newly defined target </arg1> <rel> ranges </rel> <arg2> for VAN valley levels by therapy day 3 </arg2>	0.6702812910079956
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> we </arg1> <rel> retrospectively examined </rel> <arg2> the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day later </arg2>	0.8104317784309387
Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .	<arg1> the influences of patient characteristics on the achievability of newly defined target </arg1> <rel> ranges </rel> <arg2> for VAN valley levels by therapy day later </arg2>	0.776326596736908
This document id is 30180051 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180051 </arg2>	0.9999797940254211
With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment .	<arg1> dosages </arg1> <rel> recommended </rel> <arg2> by the manufacturers </arg2>	0.9999658465385437
With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment .	<arg1> the mean trough levels </arg1> <rel> remained clearly </rel> <arg2> below the values </arg2>	0.9918078184127808
With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment .	<arg1> the values </arg1> <rel> recommended </rel> <arg2> by current therapeutic guidelines </arg2>	0.9998074173927307
This document id is 30180052 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180052 </arg2>	0.9999703168869019
When dosed according to manufacturer 's instructions , mean valley levels were significantly below the current guideline recommendation ( 15-20 mg/l for severe infections ) , particularly in renally healthy patients .	<arg1> mean valley levels </arg1> <rel> were </rel> <arg2> significantly below the current guideline recommendation When dosed according to manufacturer 's instructions </arg2>	0.9746561646461487
This document id is 30180061 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180061 </arg2>	0.9999721050262451
Even with body-weight adjusted dosages , only a minority of patients reached plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three .	<arg1> only a minority of patients </arg1> <rel> reached </rel> <arg2> plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three Even with body-weight adjusted dosages </arg2>	0.9916106462478638
Even with body-weight adjusted dosages , only a minority of patients reached plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three .	<arg1> plasma levels </arg1> <rel> meet </rel> <arg2> the guideline recommendations , particularly during the early phase of treatment until day three </arg2>	0.17774426937103271
This document id is 30180062 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180062 </arg2>	0.9999738335609436
Even with body-weight-based dosing , only a minority of patients achieved valley levels in line with recommendations , especially by therapy day 3 .	<arg1> only a minority of patients </arg1> <rel> achieved </rel> <arg2> valley levels Even with body-weight-based dosing in line with recommendations , especially by therapy day 3 </arg2>	0.7958228588104248
This document id is 30180071 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180071 </arg2>	0.9999701976776123
A moderate correlation was observed between VAN trough levels and body weight-adjusted dosage .	<arg1> A moderate correlation </arg1> <rel> was observed </rel> <arg2> between VAN trough levels and body weight-adjusted dosage </arg2>	0.9999545812606812
This document id is 30180072 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180072 </arg2>	0.9999710917472839
There was a moderate correlation of valley level with body-weight-based dosing .	<arg1> a moderate correlation </arg1> <rel> of </rel> <arg2> valley level with body-weight-based dosing </arg2>	0.941676676273346
This document id is 30180081 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180081 </arg2>	0.9999691843986511
The intraindividual variability of renal function which is commonly observed in intensive care patients further confounds the predictability of VAN exposure .	<arg1> renal function </arg1> <rel> is commonly observed </rel> <arg2> in intensive care patients </arg2>	0.9989950060844421
The intraindividual variability of renal function which is commonly observed in intensive care patients further confounds the predictability of VAN exposure .	<arg1> The intraindividual variability of renal function </arg1> <rel> confounds </rel> <arg2> the predictability of VAN exposure </arg2>	0.9997454881668091
This document id is 30180082 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180082 </arg2>	0.9999706149101257
In ICU patients , more frequent fluctuations in renal function have unpredictable effects on VAN exposure .	<arg1> more frequent fluctuations in renal function </arg1> <rel> have </rel> <arg2> unpredictable effects on VAN exposure In ICU patients </arg2>	0.9998948574066162
This document id is 30180091 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180091 </arg2>	0.9999703168869019
In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) .	<arg1> VAN dosages beyond the manufacturer recommendation </arg1> <rel> are required </rel> <arg2> to reach the target trough levels In most cases </arg2>	0.981593668460846
In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) .	<arg1> VAN dosages beyond the manufacturer recommendation </arg1> <rel> to reach </rel> <arg2> the target trough levels specified by the guidelines </arg2>	0.014343413524329662
In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) .	<arg1> the target trough levels </arg1> <rel> specified </rel> <arg2> by the guidelines </arg2>	0.9911580085754395
This document id is 30180092 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180092 </arg2>	0.9999697208404541
In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .	<arg1> VAN doses above the manufacturer 's recommendation </arg1> <rel> are needed achieve </rel> <arg2> to the current valley level target of to results In most cases </arg2>	0.4559117555618286
In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .	<arg1> doses above current valley level . The results </arg1> <rel> ranges argue </rel> <arg2> 10 to 20 mg/l for early , repeated valley level measurements even in renally healthy patients </arg2>	0.06495147198438644
In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .	<arg1> VAN doses above the manufacturer 's recommendation </arg1> <rel> are needed </rel> <arg2> In most cases to achieve the current valley level target of 10 to </arg2>	0.1020534485578537
In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .	<arg1> mg/l The results </arg1> <rel> ranges </rel> <arg2>  </arg2>	0.321999192237854
This document id is 30180101 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180101 </arg2>	0.9999783635139465
These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .	<arg1> These results </arg1> <rel> strongly support </rel> <arg2> early VAN trough level measurements in patients with normal function even renal </arg2>	0.8151181936264038
These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .	<arg1> early VAN </arg1> <rel> trough </rel> <arg2> level measurements even in patients with normal renal function </arg2>	0.6075480580329895
These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .	<arg1> These results </arg1> <rel> strongly support </rel> <arg2> repeated VAN trough level measurements even in patients with normal renal function </arg2>	0.9006087779998779
This document id is 30180102 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180102 </arg2>	0.9999781250953674
The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .	<arg1> The low exposure in the critical early phase </arg1> <rel> suggest </rel> <arg2> the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens </arg2>	0.9996090531349182
The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .	<arg1> The low exposure in the critical early phase </arg1> <rel> suggest </rel> <arg2> the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens </arg2>	0.9996108412742615
The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .	<arg1> the limited correlation of dosage </arg1> <rel> suggest </rel> <arg2> the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens </arg2>	0.9979770183563232
The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .	<arg1> the limited correlation of exposure </arg1> <rel> suggest </rel> <arg2> the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens </arg2>	0.9862168431282043
The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .	<arg1> the limited correlation of dosage </arg1> <rel> suggest </rel> <arg2> the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens </arg2>	0.9993020296096802
The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .	<arg1> the limited correlation of exposure </arg1> <rel> suggest </rel> <arg2> the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens </arg2>	0.9974182844161987
This document id is 30180111 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180111 </arg2>	0.9999781250953674
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the generally low exposure </arg1> <rel> observed </rel> <arg2> in the critical early phase </arg2>	0.9998001456260681
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> VAN MIC </arg1> <rel> ≥ </rel> <arg2> 2 mg/L </arg2>	0.9984570741653442
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the generally low exposure observed in the critical early phase </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA </arg2>	0.13850650191307068
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the limited correlation of dosage </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA </arg2>	0.9992174506187439
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> bacterial strains VAN MIC </arg1> <rel> ≥ </rel> <arg2> 2 mg/L </arg2>	0.8008607625961304
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the limited correlation of exposure </arg1> <rel> suggest at </rel> <arg2> the use of other antibiotics active against MRSA </arg2>	0.929694652557373
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> VAN MIC </arg1> <rel> ≥ </rel> <arg2> 2 mg/L </arg2>	0.9884880781173706
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the generally low exposure </arg1> <rel> observed </rel> <arg2> in the critical early phase </arg2>	0.9998986721038818
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the generally low exposure observed in the critical early phase </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs </arg2>	0.9975419044494629
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the generally low exposure observed in the critical early phase </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues </arg2>	0.9982299208641052
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the limited correlation of dosage </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs </arg2>	0.9994461536407471
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the limited correlation of dosage </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues </arg2>	0.9994490742683411
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the limited correlation of exposure </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs </arg2>	0.9986082911491394
Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .	<arg1> the limited correlation of exposure </arg1> <rel> suggest </rel> <arg2> the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues </arg2>	0.998937726020813
This document id is 30180112 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180112 </arg2>	0.9999780654907227
However , the clinical and microbiological response and the occurrence of toxicity have not been studied .	<arg1> the occurrence of toxicity </arg1> <rel> have not been studied </rel> <arg2>  </arg2>	0.9999507665634155
However , the clinical and microbiological response and the occurrence of toxicity have not been studied .	<arg1> the clinical response </arg1> <rel> have not been studied </rel> <arg2>  </arg2>	0.9999654293060303
However , the clinical and microbiological response and the occurrence of toxicity have not been studied .	<arg1> the microbiological response </arg1> <rel> have not been studied </rel> <arg2>  </arg2>	0.9999335408210754
This document id is 30180121 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30180121 </arg2>	0.99997878074646
Clinical and microbiological responses as well as toxicities were not investigated in this study .	<arg1> Clinical responses as well as toxicities </arg1> <rel> were not investigated </rel> <arg2> in this study </arg2>	0.9999557733535767
Clinical and microbiological responses as well as toxicities were not investigated in this study .	<arg1> microbiological responses as well as toxicities </arg1> <rel> were not investigated </rel> <arg2> in this study </arg2>	0.9999147057533264
This document id is 30190001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190001 </arg2>	0.9999793767929077
Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units .	<arg1> Meropenem </arg1> <rel> are commonly used </rel> <arg2> broad spectrum beta-lactam antibiotics in intensive care units </arg2>	0.941203236579895
Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units .	<arg1> piperacillin </arg1> <rel> are commonly used </rel> <arg2> broad spectrum beta-lactam antibiotics in intensive care units </arg2>	0.9783965349197388
Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units .	<arg1> ceftazidime </arg1> <rel> are commonly used </rel> <arg2> broad spectrum beta-lactam antibiotics in intensive care units </arg2>	0.9936208128929138
This document id is 30190002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190002 </arg2>	0.9999797344207764
The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity .	<arg1> The beta-lactam antibiotics meropenem </arg1> <rel> are used </rel> <arg2> in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity </arg2>	0.9977809190750122
The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity .	<arg1> The beta-lactam antibiotics piperacillin </arg1> <rel> are used </rel> <arg2> in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity </arg2>	0.9960871934890747
The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity .	<arg1> The beta-lactam antibiotics ceftazidime </arg1> <rel> are used </rel> <arg2> in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity </arg2>	0.9946544766426086
This document id is 30190011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190011 </arg2>	0.999981701374054
To improve the therapeutic outcome of the antimicrobial therapy of critically ill patients therapeutic drug monitoring is recommended .	<arg1> To improve the therapeutic outcome of the antimicrobial therapy of critically ill patients therapeutic drug monitoring </arg1> <rel> is recommended </rel> <arg2>  </arg2>	0.9925234913825989
This document id is 30190012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190012 </arg2>	0.9999813437461853
Due to strong inter- and intraindividual variations in pharmacokinetics , the establishment of therapeutic drug monitoring is recommended to improve therapeutic outcome .	<arg1> the establishment of therapeutic drug monitoring </arg1> <rel> is recommended </rel> <arg2> to improve therapeutic outcome </arg2>	0.9971718192100525
Due to strong inter- and intraindividual variations in pharmacokinetics , the establishment of therapeutic drug monitoring is recommended to improve therapeutic outcome .	<arg1> the establishment of therapeutic drug monitoring </arg1> <rel> to improve </rel> <arg2> therapeutic outcome </arg2>	0.9637319445610046
This document id is 30190021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190021 </arg2>	0.9999791383743286
Therefore an analytical method was established measuring fluctuating serum levels during therapy .	<arg1> an analytical method </arg1> <rel> was established </rel> <arg2> measuring fluctuating serum levels during therapy </arg2>	0.999325692653656
Therefore an analytical method was established measuring fluctuating serum levels during therapy .	<arg1> an analytical method </arg1> <rel> measuring </rel> <arg2> fluctuating serum levels during therapy </arg2>	0.9908706545829773
This document id is 30190022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190022 </arg2>	0.9999810457229614
In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .	<arg1> an analytical HPLC method </arg1> <rel> is described </rel> <arg2> In the following </arg2>	0.9998321533203125
In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .	<arg1> which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml </arg1> <rel> can be determined quickly </rel> <arg2>  </arg2>	0.7510457634925842
In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .	<arg1> an analytical HPLC method </arg1> <rel> is described </rel> <arg2> In the following </arg2>	0.9998321533203125
In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .	<arg1> which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml </arg1> <rel> can be determined reliably </rel> <arg2>  </arg2>	0.5301108956336975
This document id is 30190031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190031 </arg2>	0.9999847412109375
A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .	<arg1> A simple high-performance liquid chromatography ( HPLC ) method with diode array detection </arg1> <rel> was developed </rel> <arg2> for simultaneous quantification of these antimicrobial agents </arg2>	0.9978786110877991
A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .	<arg1> A simple high-performance liquid chromatography ( HPLC ) method with diode array detection </arg1> <rel> was validated </rel> <arg2> for simultaneous quantification of these antimicrobial agents </arg2>	0.9989348649978638
A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .	<arg1> A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection </arg1> <rel> was developed </rel> <arg2> for simultaneous quantification of these antimicrobial agents </arg2>	0.998887300491333
A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .	<arg1> A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection </arg1> <rel> was validated </rel> <arg2> for simultaneous quantification of these antimicrobial agents </arg2>	0.9993870258331299
This document id is 30190032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190032 </arg2>	0.999984085559845
The serum levels determined can then be used as a valid basis for further therapy decisions .	<arg1> The serum levels </arg1> <rel> determined </rel> <arg2>  </arg2>	0.9981598258018494
The serum levels determined can then be used as a valid basis for further therapy decisions .	<arg1> The serum levels determined </arg1> <rel> can be used </rel> <arg2> as a valid basis for further therapy decisions then </arg2>	0.9978861212730408
This document id is 30190041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190041 </arg2>	0.9999845623970032
For sample preparation a sample amount of 250 µl serum was spiked with cefotaxime as an internal standard .	<arg1> a sample amount of 250 µl serum </arg1> <rel> was spiked </rel> <arg2> with cefotaxime as an internal standard For sample preparation </arg2>	0.9986521601676941
This document id is 30190051 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190051 </arg2>	0.9999845027923584
Afterwards protein was precipitated using acetonitrile/methanol ( 1:1 ) .	<arg1> protein </arg1> <rel> was precipitated </rel> <arg2> Afterwards </arg2>	0.9925524592399597
This document id is 30190061 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190061 </arg2>	0.9999808073043823
The supernatant was transferred to HPLC .	<arg1> The supernatant </arg1> <rel> was transferred </rel> <arg2> to HPLC </arg2>	0.9999936819076538
This document id is 30190071 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190071 </arg2>	0.9999802708625793
A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile and a pH 2.2 phosphoric acid solution was used for separation .	<arg1> A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile </arg1> <rel> was used </rel> <arg2> for separation </arg2>	0.9948905110359192
A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile and a pH 2.2 phosphoric acid solution was used for separation .	<arg1> A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a pH 2.2 phosphoric acid solution </arg1> <rel> was used </rel> <arg2> for separation </arg2>	0.9850505590438843
This document id is 30190081 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190081 </arg2>	0.9999791979789734
Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively .	<arg1> Peaks of interest </arg1> <rel> were detected respectively </rel> <arg2> at 240 nm </arg2>	0.9790279269218445
Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively .	<arg1> Peaks of interest </arg1> <rel> were detected respectively </rel> <arg2> at 298 nm </arg2>	0.980464518070221
Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively .	<arg1> Peaks of interest </arg1> <rel> were detected respectively </rel> <arg2> at 310 nm </arg2>	0.9837861061096191
This document id is 30190091 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190091 </arg2>	0.9999800324440002
The method developed shows a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml for each antibiotic in the serum samples .	<arg1> The method </arg1> <rel> developed </rel> <arg2>  </arg2>	0.9998940229415894
The method developed shows a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml for each antibiotic in the serum samples .	<arg1> The method developed </arg1> <rel> shows </rel> <arg2> a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml </arg2>	0.6117441654205322
This document id is 30190101 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190101 </arg2>	0.9999862313270569
Validation has demonstrated the method to be accurate and precise too .	<arg1> Validation </arg1> <rel> has demonstrated </rel> <arg2> the method to be accurate too </arg2>	0.9999666810035706
Validation has demonstrated the method to be accurate and precise too .	<arg1> the method </arg1> <rel> to be too </rel> <arg2> accurate </arg2>	0.9921674728393555
Validation has demonstrated the method to be accurate and precise too .	<arg1> Validation </arg1> <rel> has demonstrated </rel> <arg2> the method to be precise too </arg2>	0.9997155070304871
Validation has demonstrated the method to be accurate and precise too .	<arg1> the method </arg1> <rel> to be too </rel> <arg2> precise </arg2>	0.9956284165382385
This document id is 30190111 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190111 </arg2>	0.9999850988388062
No interferences with other common drugs except metamizole ( dipyrone ) and ceftazidime were detected .	<arg1> No interferences with other common drugs except metamizole </arg1> <rel> were detected </rel> <arg2>  </arg2>	0.9873977303504944
No interferences with other common drugs except metamizole ( dipyrone ) and ceftazidime were detected .	<arg1> No interferences with other common drugs except ceftazidime </arg1> <rel> were detected </rel> <arg2>  </arg2>	0.9984590411186218
This document id is 30190121 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30190121 </arg2>	0.9999849200248718
The method is currently used in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients .	<arg1> The method </arg1> <rel> is used </rel> <arg2> in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients currently </arg2>	0.9994067549705505
This document id is 30200001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200001 </arg2>	0.9999727010726929
The frequency of bacterial infections for which antibiotics no longer work is increasing worldwide due to the development of antibiotic resistance among pathogens .	<arg1> The frequency of bacterial infections </arg1> <rel> is increasing </rel> <arg2> worldwide due to the development of antibiotic resistance among pathogens </arg2>	0.996236264705658
This document id is 30200002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200002 </arg2>	0.9999698996543884
The frequency of bacterial infections for which antibiotics are no longer effective is increasing worldwide due to the development of resistance in pathogens .	<arg1> bacterial infections </arg1> <rel> are </rel> <arg2> antibiotics no longer effective </arg2>	0.962838888168335
The frequency of bacterial infections for which antibiotics are no longer effective is increasing worldwide due to the development of resistance in pathogens .	<arg1> The frequency of bacterial infections </arg1> <rel> is increasing </rel> <arg2> worldwide due to the development of resistance in pathogens </arg2>	0.08216340094804764
This document id is 30200011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200011 </arg2>	0.9999744892120361
Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances .	<arg1> Research topics , in order </arg1> <rel> include </rel> <arg2> the development of new antibiotics </arg2>	0.9828197956085205
Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances .	<arg1> Research topics , in order </arg1> <rel> include </rel> <arg2> the reactivation of existing antibacterial agents </arg2>	0.9745433926582336
Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances .	<arg1> Research topics , in order </arg1> <rel> include </rel> <arg2> the finding of resistance-modifying properties of natural substances </arg2>	0.9756063222885132
This document id is 30200012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200012 </arg2>	0.9999746680259705
To counter this threat , research is being conducted - in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products .	<arg1> research </arg1> <rel> is being conducted </rel> <arg2> To counter this threat in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products </arg2>	0.8932165503501892
This document id is 30200021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200021 </arg2>	0.9999697208404541
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work </arg2>	0.9867690205574036
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) with lysozyme amplify the effects of a carbapenem- ( ) against the bacterial pathogens </arg2>	0.7452995181083679
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> from cloves </arg1> <rel> combined </rel> <arg2> how the essential oils ( Syzygium aromaticum ) with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Pseudomonas aeruginosa </arg2>	0.6301761865615845
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cloves combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Pseudomonas aeruginosa </arg2>	0.6866996884346008
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the bacterial pathogens </arg1> <rel> Pseudomonas aeruginosa </rel> <arg2>  </arg2>	0.7494341731071472
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae In the present work </arg2>	0.9442557096481323
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens pneumoniae </arg2>	0.7205353379249573
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cloves </arg1> <rel> combined </rel> <arg2> how ( Syzygium aromaticum ) with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.6331626772880554
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cloves combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of a carbapenem- ( imipenem bacterial pathogens Klebsiella pneumoniae </arg2>	0.727026641368866
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> ) against the bacterial pathogens </arg1> <rel> Klebsiella pneumoniae </rel> <arg2>  </arg2>	0.6089996695518494
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens In the present work </arg2>	0.9969750642776489
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens </arg2>	0.8626493811607361
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cloves </arg1> <rel> combined </rel> <arg2> how ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa </arg2>	0.6298813819885254
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cloves combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa </arg2>	0.8473782539367676
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae In the present work </arg2>	0.9441999197006226
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.7829353213310242
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> essential oils from cloves </arg1> <rel> combined </rel> <arg2> how the ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.6362032294273376
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cloves combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.8788118958473206
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the bacterial pathogens </arg1> <rel> Klebsiella pneumoniae </rel> <arg2>  </arg2>	0.78752601146698
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work </arg2>	0.996231734752655
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> the essential oils from cinnamon ) with lysozyme a ) against the bacterial pathogens Pseudomonas aeruginosa </arg2>	0.5493137836456299
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cinnamon combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of a carbapenem- imipenem </arg2>	0.9038478136062622
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> ( ) against the bacterial pathogens </arg1> <rel> Pseudomonas aeruginosa </rel> <arg2>  </arg2>	0.7068426609039307
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae In the present work </arg2>	0.9343464970588684
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> the essential oils from cinnamon ) with lysozyme effects a ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.5468484163284302
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> investigate </rel> <arg2> how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.45378580689430237
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cinnamon combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of a carbapenem- </arg2>	0.9614182710647583
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens In the present work </arg2>	0.9983609914779663
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens aeruginosa </arg2>	0.8369737267494202
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cinnamon ( Cinnamomum verum ) </arg1> <rel> combined </rel> <arg2> how with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa </arg2>	0.7666360139846802
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cinnamon combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa </arg2>	0.9050578474998474
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> bacterial pathogens </arg1> <rel> Pseudomonas aeruginosa </rel> <arg2>  </arg2>	0.8497187495231628
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae In the present work </arg2>	0.9824232459068298
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cinnamon ( Cinnamomum verum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.6683931946754456
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the checkerboard microdilution method ( Cinnamomum verum </arg1> <rel> combined </rel> <arg2> how the essential oils from cinnamon ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.4156155288219452
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> the essential oils from cinnamon combined with lysozyme </arg1> <rel> amplify </rel> <arg2> the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae </arg2>	0.9233815670013428
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .	<arg1> ) the bacterial pathogens </arg1> <rel> pneumoniae </rel> <arg2> Klebsiella </arg2>	0.6700640916824341
This document id is 30200022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200022 </arg2>	0.9999738335609436
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens respectively In the present work </arg2>	0.9447805285453796
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens aeruginosa , </arg2>	0.7341575026512146
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves </arg1> <rel> combined </rel> <arg2> how with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.7610530257225037
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme </arg1> <rel> enhance </rel> <arg2> the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.6195712685585022
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work </arg2>	0.9140992760658264
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae respectively </arg2>	0.7857092022895813
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves </arg1> <rel> combined </rel> <arg2> how with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.8182816505432129
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme </arg1> <rel> enhance </rel> <arg2> the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.6033034920692444
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens respectively In the present work </arg2>	0.9487146139144897
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , </arg2>	0.6451663374900818
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves </arg1> <rel> combined </rel> <arg2> how ( Syzygium aromaticum ) with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.5509533286094666
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves combined with lysozyme </arg1> <rel> enhance </rel> <arg2> the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.7938509583473206
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> bacterial pathogens </arg1> <rel> Pseudomonas aeruginosa , respectively </rel> <arg2>  </arg2>	0.47982561588287354
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens pneumoniae , respectively In the present work </arg2>	0.8246976733207703
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.6742790937423706
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves </arg1> <rel> combined </rel> <arg2> how with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.8105319738388062
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme </arg1> <rel> enhance </rel> <arg2> the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.6081961393356323
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens In the present work </arg2>	0.9954966902732849
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens </arg2>	0.7664970755577087
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree </arg1> <rel> combined </rel> <arg2> how ( Cinnamomum verum ) with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.5210705399513245
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree combined with </arg1> <rel> enhance </rel> <arg2> lysozyme the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.5940054059028625
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work </arg2>	0.8819602727890015
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae respectively </arg2>	0.661297082901001
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree </arg1> <rel> combined </rel> <arg2> with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.7631229758262634
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme </arg1> <rel> enhance </rel> <arg2> the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.5990002751350403
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens In the present work </arg2>	0.9951468706130981
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens </arg2>	0.733424186706543
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree </arg1> <rel> combined </rel> <arg2> how ( Cinnamomum verum ) with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.532768726348877
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree combined </arg1> <rel> enhance </rel> <arg2> with lysozyme the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively </arg2>	0.5998833775520325
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> was used </rel> <arg2> to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively In the present work </arg2>	0.5128477811813354
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the checkerboard microdilution method </arg1> <rel> to investigate </rel> <arg2> how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens pneumoniae , respectively </arg2>	0.5359886288642883
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree verum ) </arg1> <rel> combined </rel> <arg2> how with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.6498036980628967
In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .	<arg1> the essential oils from the bark of the cinnamon tree ( Cinnamomum combined with lysozyme </arg1> <rel> enhance </rel> <arg2> the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively </arg2>	0.6373131275177002
This document id is 30200031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200031 </arg2>	0.9999736547470093
The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .	<arg1> The results </arg1> <rel> indicate </rel> <arg2> that the essential oils of both plant species thus significantly increase the antibiotic effects </arg2>	0.9998876452445984
The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .	<arg1> the essential oils of both plant species </arg1> <rel> significantly increase </rel> <arg2> the antibiotic effects </arg2>	0.9791964292526245
The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .	<arg1> The results </arg1> <rel> indicate </rel> <arg2> that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species </arg2>	0.9999259114265442
The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .	<arg1> the essential oils of both plant species </arg1> <rel> reduce </rel> <arg2> the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species </arg2>	0.9998476505279541
The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .	<arg1> The results </arg1> <rel> indicate </rel> <arg2> that the essential oils of both plant species reduce the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species </arg2>	0.9999235272407532
The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .	<arg1> the essential oils of both plant species </arg1> <rel> reduce </rel> <arg2> the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species </arg2>	0.9998510479927063
This document id is 30200032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200032 </arg2>	0.9999728202819824
The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .	<arg1> The results </arg1> <rel> show </rel> <arg2> that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species </arg2>	0.9978430271148682
The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .	<arg1> the essential oils of both plant species </arg1> <rel> decrease </rel> <arg2> the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species </arg2>	0.9983083009719849
The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .	<arg1> the essential oils of both plant species </arg1> <rel> significantly enhancing </rel> <arg2> antibiotic efficacy </arg2>	0.5960386395454407
The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .	<arg1> The results </arg1> <rel> show </rel> <arg2> that the essential oils of both plant species decrease the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species </arg2>	0.9978111982345581
The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .	<arg1> the essential oils of both plant species </arg1> <rel> decrease </rel> <arg2> the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species </arg2>	0.9982824921607971
This document id is 30200041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200041 </arg2>	0.9999659061431885
The observed potent resistance-modifying properties of the essential oils favour further investigations of the phenylpropanoids as the main components of both oils and other natural substances in this context .	<arg1> The observed potent resistance-modifying properties of the essential oils </arg1> <rel> favour </rel> <arg2> further investigations of the phenylpropanoids as the main components of both oils in this context </arg2>	0.9988951683044434
The observed potent resistance-modifying properties of the essential oils favour further investigations of the phenylpropanoids as the main components of both oils and other natural substances in this context .	<arg1> The observed potent resistance-modifying properties of the essential oils </arg1> <rel> favour </rel> <arg2> further investigations of the phenylpropanoids as the main components of both other natural substances in this context </arg2>	0.9985643029212952
This document id is 30200042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30200042 </arg2>	0.9999619722366333
The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .	<arg1> The potent resistance-modifying properties of the essential oils </arg1> <rel> suggest </rel> <arg2> further investigation of phenylpropanoids as major components of both oils in this context is promising </arg2>	0.9977886080741882
The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .	<arg1> further investigation of phenylpropanoids as major components of both oils in this context </arg1> <rel> is </rel> <arg2> promising </arg2>	0.998630702495575
The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .	<arg1> The potent resistance-modifying properties of the essential oils </arg1> <rel> suggest </rel> <arg2> further investigation of phenylpropanoids as major components of both other natural products in this context is promising </arg2>	0.9938572645187378
The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .	<arg1> further investigation of phenylpropanoids as major components of both other natural products in this context </arg1> <rel> is </rel> <arg2> promising </arg2>	0.9900619387626648
This document id is 30210001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210001 </arg2>	0.9999731183052063
Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available .	<arg1> researchers </arg1> <rel> are looking </rel> <arg2> for promising therapy in substances </arg2>	0.9996620416641235
Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available .	<arg1> substances </arg1> <rel> are </rel> <arg2> already available </arg2>	0.9999625086784363
Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available .	<arg1> researchers </arg1> <rel> are looking </rel> <arg2> for effective therapy in substances </arg2>	0.9996123313903809
This document id is 30210002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210002 </arg2>	0.9999695420265198
Since there is still no reliable therapy and not enough approved vaccines against SARS-CoV-2 , research is looking for promising , effective substances that are already available .	<arg1> research </arg1> <rel> is looking </rel> <arg2> for promising , effective substances </arg2>	0.9988390207290649
Since there is still no reliable therapy and not enough approved vaccines against SARS-CoV-2 , research is looking for promising , effective substances that are already available .	<arg1> promising , effective substances </arg1> <rel> are </rel> <arg2> already available </arg2>	0.997160792350769
This document id is 30210011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210011 </arg2>	0.9999714493751526
The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 .	<arg1> The objective of the current study </arg1> <rel> is </rel> <arg2> to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 </arg2>	0.9495596289634705
The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 .	<arg1> the herbal preparation </arg1> <rel> has </rel> <arg2> in vitro antiviral properties </arg2>	0.9205092787742615
This document id is 30210012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210012 </arg2>	0.9999752640724182
This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .	<arg1> it </arg1> <rel> has been shown </rel> <arg2> effective against other viruses already </arg2>	0.44641292095184326
This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .	<arg1> it </arg1> <rel> to be </rel> <arg2> antiviral properties against SARS-CoV-2 effective against several other viruses </arg2>	0.7553823590278625
This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .	<arg1> This study </arg1> <rel> will investigate </rel> <arg2> whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 </arg2>	0.9776239991188049
This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .	<arg1> the herbal preparation </arg1> <rel> has </rel> <arg2> in vitro antiviral properties against SARS-CoV-2 </arg2>	0.7100401520729065
This document id is 30210021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210021 </arg2>	0.9999663233757019
CPE has already proved to be effective against several other viruses .	<arg1> CPE </arg1> <rel> has proved </rel> <arg2> already </arg2>	0.9849674105644226
CPE has already proved to be effective against several other viruses .	<arg1> CPE </arg1> <rel> to be </rel> <arg2> effective against several other viruses </arg2>	0.9989453554153442
This document id is 30210022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210022 </arg2>	0.9999650120735168
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .	<arg1> cell cultures </arg1> <rel> were infected </rel> <arg2> with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy </arg2>	0.9999086260795593
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .	<arg1> cell cultures </arg1> <rel> using </rel> <arg2> Cystus Pandalis® extract </arg2>	0.9226111173629761
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .	<arg1> the reduction in infection rate </arg1> <rel> was evaluated </rel> <arg2> by comparing units At the Fraunhofer Institute for Cell Therapy </arg2>	0.8686486482620239
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .	<arg1> the reduction in infection rate </arg1> <rel> by comparing </rel> <arg2> foci-forming units </arg2>	0.9991490840911865
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .	<arg1> cell cultures </arg1> <rel> were infected </rel> <arg2> with SARS-CoV-2 using Cystus Pandalis® At the Fraunhofer Institute for Immunology </arg2>	0.9125235676765442
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .	<arg1> the reduction in infection rate </arg1> <rel> was evaluated </rel> <arg2> by comparing foci-forming units At the Fraunhofer Institute for Immunology </arg2>	0.8772674202919006
This document id is 30210031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210031 </arg2>	0.9999749064445496
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .	<arg1> cell cultures </arg1> <rel> treated </rel> <arg2> with Cystus Pandalis® extract </arg2>	0.9996587634086609
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .	<arg1> ( IZI ) cell cultures treated with Cystus Pandalis® extract </arg1> <rel> were infected </rel> <arg2> with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy </arg2>	0.8285834789276123
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .	<arg1> the reduction in the infection rate </arg1> <rel> was evaluated </rel> <arg2> by comparing focus-forming units At the Fraunhofer Institute for Cell Therapy </arg2>	0.8416394591331482
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .	<arg1> IZI ) cell cultures treated with Cystus Pandalis® extract </arg1> <rel> were infected </rel> <arg2> with SARS-CoV-2 At the Fraunhofer Institute for Immunology </arg2>	0.8157186508178711
At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .	<arg1> the reduction in the infection rate </arg1> <rel> was evaluated </rel> <arg2> by comparing focus-forming units At the Fraunhofer Institute for Immunology </arg2>	0.8547228574752808
This document id is 30210032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210032 </arg2>	0.9999772906303406
An almost complete reduction in infection rate by CPE was observed at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml .	<arg1> An almost complete reduction in infection rate by CPE </arg1> <rel> was observed </rel> <arg2> at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml </arg2>	0.9991426467895508
This document id is 30210041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210041 </arg2>	0.9999762177467346
An almost complete reduction in the CPE infection rate was observed at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml .	<arg1> An almost complete reduction in the CPE infection rate </arg1> <rel> was observed </rel> <arg2> at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml </arg2>	0.9998639822006226
This document id is 30210042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210042 </arg2>	0.9999744296073914
The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .	<arg1> The mechanism of action of this extract </arg1> <rel> may be based </rel> <arg2> on the high polymer polyphenols </arg2>	0.9996605515480042
The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .	<arg1> the high polymer polyphenols </arg1> <rel> coat </rel> <arg2> certain viral epitopes </arg2>	0.9982199668884277
The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .	<arg1> the high polymer polyphenols that , </arg1> <rel> certain viral epitopes causing </rel> <arg2> CPE to act as an entry inhibitor </arg2>	0.37341511249542236
The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .	<arg1> CPE </arg1> <rel> to act </rel> <arg2> as an entry inhibitor </arg2>	0.9782326817512512
This document id is 30210051 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210051 </arg2>	0.9999741911888123
The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor .	<arg1> The mechanism of action of this extract </arg1> <rel> may be based </rel> <arg2> on the highly polymeric polyphenols </arg2>	0.9998184442520142
The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor .	<arg1> the highly polymeric polyphenols </arg1> <rel> envelop </rel> <arg2> certain viral epitopes , whereby CPE acts as an entry inhibitor </arg2>	0.9788680076599121
The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor .	<arg1> CPE </arg1> <rel> acts </rel> <arg2> as an entry inhibitor </arg2>	0.9996973872184753
This document id is 30210052 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210052 </arg2>	0.9999746680259705
Due to the high in vitro activity , it seems reasonable to use CPE as prophylaxis against infections with SARS-CoV-2 .	<arg1> it </arg1> <rel> to use </rel> <arg2> CPE as prophylaxis against infections with SARS-CoV-2 </arg2>	0.9484862089157104
This document id is 30210061 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30210061 </arg2>	0.9999756813049316
The high in vitro activity of CPE seems to make it a reasonable candidate for prophylaxis against SARS-CoV-2 .	<arg1> The high in vitro activity of CPE </arg1> <rel> seems </rel> <arg2>  </arg2>	0.9999770522117615
The high in vitro activity of CPE seems to make it a reasonable candidate for prophylaxis against SARS-CoV-2 .	<arg1> The high in vitro activity of CPE </arg1> <rel> to make </rel> <arg2> it a reasonable candidate for prophylaxis against SARS-CoV-2 </arg2>	0.9996183514595032
This document id is 30220001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220001 </arg2>	0.9999701976776123
Fruits from Apium graveolens ( celery ) are used traditionally in Persian and European medicine for the treatment of uncomplicated urinary tract infections .	<arg1> Fruits from Apium graveolens </arg1> <rel> are used traditionally </rel> <arg2> in Persian medicine for the treatment of uncomplicated urinary tract infections </arg2>	0.9918849468231201
Fruits from Apium graveolens ( celery ) are used traditionally in Persian and European medicine for the treatment of uncomplicated urinary tract infections .	<arg1> Fruits from Apium graveolens </arg1> <rel> are used traditionally </rel> <arg2> in European medicine for the treatment of uncomplicated urinary tract infections </arg2>	0.9937748908996582
This document id is 30220002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220002 </arg2>	0.9999706149101257
The fruits of Apium graveolens L. ( celery ) are used in traditional Persian and European medicine for the treatment of uncomplicated urinary tract infections ( UTI ) .	<arg1> The fruits of Apium graveolens L. </arg1> <rel> are used </rel> <arg2> in traditional Persian medicine for the treatment of uncomplicated urinary tract infections </arg2>	0.9993604421615601
The fruits of Apium graveolens L. ( celery ) are used in traditional Persian and European medicine for the treatment of uncomplicated urinary tract infections ( UTI ) .	<arg1> The fruits of Apium graveolens L. </arg1> <rel> are used </rel> <arg2> in traditional European medicine for the treatment of uncomplicated urinary tract infections </arg2>	0.9993773698806763
This document id is 30220011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220011 </arg2>	0.9999768137931824
No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .	<arg1> No data </arg1> <rel> are </rel> <arg2> available on A. graveolens on sensing of the bacteria extract quorum </arg2>	0.7259237766265869
No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .	<arg1> No data </arg1> <rel> are </rel> <arg2> available on A. graveolens extract on the interplay between uropathogenic E. coli </arg2>	0.8863183259963989
No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .	<arg1> No data </arg1> <rel> are </rel> <arg2> available on A. graveolens extract on the interplay between the eukaryotic host cells </arg2>	0.890802264213562
This document id is 30220012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220012 </arg2>	0.9999759793281555
To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .	<arg1> no data </arg1> <rel> are </rel> <arg2> available investigating corresponding To date </arg2>	0.9408833384513855
To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .	<arg1> no data </arg1> <rel> investigating </rel> <arg2> the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bacterial quorum sensing </arg2>	0.9991609454154968
To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .	<arg1> no data </arg1> <rel> are </rel> <arg2> available investigating influence of corresponding drug extracts with regard to To date </arg2>	0.752811849117279
To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .	<arg1> no data </arg1> <rel> investigating </rel> <arg2> the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder </arg2>	0.9997017979621887
To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .	<arg1> no data </arg1> <rel> are </rel> <arg2> available investigating influence of corresponding drug extracts with regard To date </arg2>	0.736960768699646
To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .	<arg1> no data </arg1> <rel> investigating </rel> <arg2> the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from kidney </arg2>	0.9996501803398132
This document id is 30220021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220021 </arg2>	0.9999728202819824
The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .	<arg1> The present study </arg1> <rel> aimed to </rel> <arg2> correlate these effects with in vivo data </arg2>	0.7689141035079956
The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .	<arg1> The present study in vivo data </arg1> <rel> correlate obtained </rel> <arg2> these effects with by an animal infection model </arg2>	0.12580259144306183
The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .	<arg1> The present study </arg1> <rel> aimed </rel> <arg2> to characterize an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays </arg2>	0.9888315200805664
The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .	<arg1> The present study </arg1> <rel> aimed to characterize </rel> <arg2> an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays </arg2>	0.9933945536613464
The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .	<arg1> The present study </arg1> <rel> aimed </rel> <arg2> to characterize an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays </arg2>	0.8456900119781494
The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .	<arg1> The present study </arg1> <rel> aimed to characterize </rel> <arg2> an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays </arg2>	0.9888941645622253
This document id is 30220022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220022 </arg2>	0.9999775290489197
The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .	<arg1> The present studies </arg1> <rel> describe </rel> <arg2> a marked anti-adhesive effect of an extract of A. graveolens </arg2>	0.999976396560669
The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .	<arg1> A. graveolens </arg1> <rel> using </rel> <arg2> in vitro studies </arg2>	0.9996985793113708
The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .	<arg1> The present studies </arg1> <rel> describe </rel> <arg2> a marked anti-adhesive effect of an extract of A. graveolens </arg2>	0.9999706149101257
The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .	<arg1> A. graveolens </arg1> <rel> using </rel> <arg2> in vivo studies in the mouse infection model </arg2>	0.8901506662368774
The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .	<arg1> The present studies </arg1> <rel> describe </rel> <arg2> a marked anti-quorum sensing effect of an extract of A. graveolens </arg2>	0.9999562501907349
The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .	<arg1> A. graveolens </arg1> <rel> sensing using </rel> <arg2> in vivo studies in the mouse infection model </arg2>	0.29352155327796936
This document id is 30220031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220031 </arg2>	0.9999808073043823
Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells .	<arg1> Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits </arg1> <rel> was characterized </rel> <arg2> by UHPLC/+ESI-QTOF-MS </arg2>	0.9994382262229919
Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells .	<arg1> Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits </arg1> <rel> was investigated </rel> <arg2> on antiproliferative activity against UPEC </arg2>	0.9965612888336182
Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells .	<arg1> Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits </arg1> <rel> was investigated </rel> <arg2> on antiproliferative activity against human T24 bladder cells </arg2>	0.9986039996147156
This document id is 30220032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220032 </arg2>	0.9999786019325256
A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells .	<arg1> A hydroalcoholic extract EtOH-water , 1:1 ) of A. graveolens fruit </arg1> <rel> was phytochemically characterized </rel> <arg2> by UHPLC/+ESI-QTOF-MS </arg2>	0.8867824077606201
A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells .	<arg1> extract EtOH-water , 1:1 ) of A. graveolens fruit </arg1> <rel> was evaluated </rel> <arg2> for antiproliferative properties against UPEC ( strain </arg2>	0.8194168210029602
A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells .	<arg1> extract ; EtOH-water , 1:1 ) of A. graveolens fruit </arg1> <rel> was evaluated </rel> <arg2> for antiproliferative properties against human T24 blast cells </arg2>	0.9509958028793335
This document id is 30220041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220041 </arg2>	0.9999796152114868
Antiadhesive properties of CSE were investigated within two different in vitro adhesion assays .	<arg1> Antiadhesive properties of CSE </arg1> <rel> were investigated </rel> <arg2> within two different in vitro adhesion assays </arg2>	0.9992160201072693
This document id is 30220042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220042 </arg2>	0.9999770522117615
Anti-adhesive effects of CSE were tested by two in vitro adhesion assays .	<arg1> Anti-adhesive effects of CSE </arg1> <rel> were tested </rel> <arg2> by two in vitro adhesion assays </arg2>	0.9999845623970032
This document id is 30220051 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220051 </arg2>	0.9999798536300659
For in vivo studies BALB/c mice were used in an UPEC infection model .	<arg1> BALB/c mice </arg1> <rel> were used </rel> <arg2> in an UPEC infection model For in vivo studies </arg2>	0.9980484843254089
This document id is 30220052 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220052 </arg2>	0.9999741911888123
For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .	<arg1> BALB/c mice </arg1> <rel> were used </rel> <arg2> in a UPEC infection model For in vivo studies </arg2>	0.9999684691429138
For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .	<arg1> the effect of CSE on bacterial load in bladder tissues </arg1> <rel> was investigated respectively </rel> <arg2> in the context of 4- pretreatment For in vivo studies </arg2>	0.8948256969451904
For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .	<arg1> the effect of CSE on bacterial load in bladder tissues </arg1> <rel> was investigated respectively </rel> <arg2> in the context of 7-day pretreatment For in vivo studies </arg2>	0.8475118279457092
For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .	<arg1> the effect of CSE on bacterial load in kidney tissues </arg1> <rel> was investigated respectively </rel> <arg2> in the context of 4- pretreatment For in vivo studies </arg2>	0.89130038022995
For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .	<arg1> the effect of CSE on bacterial load in kidney tissues </arg1> <rel> was investigated </rel> <arg2> in the context of 7-day pretreatment For in vivo studies </arg2>	0.9995770454406738
This document id is 30220061 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220061 </arg2>	0.9999778270721436
The effect of CSE on bacterial load in bladder tissue was monitored within a 4- and 7 days pretreatment ( 200 , 500 mg/kg ) of the animals .	<arg1> The effect of CSE on bacterial load in bladder tissue </arg1> <rel> was monitored </rel> <arg2> within a 4- days pretreatment </arg2>	0.999931812286377
The effect of CSE on bacterial load in bladder tissue was monitored within a 4- and 7 days pretreatment ( 200 , 500 mg/kg ) of the animals .	<arg1> The effect of CSE on bacterial load in bladder tissue </arg1> <rel> was monitored </rel> <arg2> within a 7 days pretreatment the </arg2>	0.8834129571914673
This document id is 30220062 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220062 </arg2>	0.9999778866767883
CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins .	<arg1> CSE </arg1> <rel> is phytochemically characterized </rel> <arg2> by the presence of luteolin glycosides </arg2>	0.9986887574195862
CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins .	<arg1> CSE </arg1> <rel> is phytochemically characterized </rel> <arg2> by the presence of similar flavones </arg2>	0.9985303282737732
CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins .	<arg1> CSE </arg1> <rel> is phytochemically characterized </rel> <arg2> by the presence of furanocoumarins </arg2>	0.998397946357727
This document id is 30220071 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220071 </arg2>	0.9999767541885376
CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .	<arg1> CSE </arg1> <rel> was dominated </rel> <arg2> by the presence of luteolin-glycosides besides furocoumarins </arg2>	0.9999909400939941
CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .	<arg1> CSE </arg1> <rel> was dominated </rel> <arg2> by the presence of related flavones besides furocoumarins </arg2>	0.9999873042106628
This document id is 30220072 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220072 </arg2>	0.9999750852584839
CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .	<arg1> CSE </arg1> <rel> shows </rel> <arg2> no cytotoxic effects against UPEC </arg2>	0.999993085861206
CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .	<arg1> CSE </arg1> <rel> shows </rel> <arg2> no cytotoxic effects against blast cells </arg2>	0.9999926686286926
CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .	<arg1> CSE </arg1> <rel> exhibits </rel> <arg2> concentration-dependent antiadhesive effects against UPEC strain </arg2>	0.9892802834510803
CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .	<arg1> CSE </arg1> <rel> exhibits </rel> <arg2> concentration-dependent antiadhesive effects against UTI89 </arg2>	0.9999220967292786
This document id is 30220081 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220081 </arg2>	0.9999744296073914
CSE had no cytotoxic effects against UPEC and bladder cells .	<arg1> CSE </arg1> <rel> had </rel> <arg2> no cytotoxic effects against UPEC </arg2>	0.9999945759773254
CSE had no cytotoxic effects against UPEC and bladder cells .	<arg1> CSE </arg1> <rel> had </rel> <arg2> no cytotoxic effects against bladder cells </arg2>	0.999993085861206
This document id is 30220082 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220082 </arg2>	0.9999743103981018
CSE inhibits bacterial quorum sensing in a concentration-dependent manner .	<arg1> CSE </arg1> <rel> inhibits </rel> <arg2> bacterial quorum sensing in a concentration-dependent manner </arg2>	0.9996129274368286
This document id is 30220091 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220091 </arg2>	0.9999760389328003
CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .	<arg1> CSE </arg1> <rel> exerts </rel> <arg2> a dose dependent antiadhesive activity against UPEC </arg2>	0.9957309365272522
CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .	<arg1> a dose dependent antiadhesive activity against UPEC </arg1> <rel> strains </rel> <arg2> NU14 </arg2>	0.7809035181999207
CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .	<arg1> a dose dependent antiadhesive activity against UPEC </arg1> <rel> strains </rel> <arg2> UTI89 </arg2>	0.798789918422699
This document id is 30220092 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220092 </arg2>	0.9999744296073914
In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .	<arg1> 4 day pretreatment of mice with CSE </arg1> <rel> followed </rel> <arg2> by transurethal UPEC NU14 infection </arg2>	0.7500959038734436
In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .	<arg1> In vivo 4 day pretreatment of mice with CSE </arg1> <rel> significantly inhibited </rel> <arg2> bacterial load in bladder tissue </arg2>	0.28929170966148376
In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .	<arg1> 7 day pretreatment of mice with CSE </arg1> <rel> followed </rel> <arg2> by transurethal UPEC NU14 infection </arg2>	0.7656466364860535
In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .	<arg1> In vivo 7 day pretreatment of mice with CSE </arg1> <rel> significantly inhibited </rel> <arg2> bacterial load in bladder tissue </arg2>	0.28409263491630554
This document id is 30220101 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220101 </arg2>	0.9999808669090271
CSE inhibited in a concentration-dependent manner bacterial quorum sensing .	<arg1> CSE </arg1> <rel> inhibited </rel> <arg2> in a concentration-dependent manner </arg2>	0.9948098659515381
CSE inhibited in a concentration-dependent manner bacterial quorum sensing .	<arg1> a concentration-dependent manner bacterial quorum </arg1> <rel> sensing </rel> <arg2>  </arg2>	0.7734676599502563
This document id is 30220102 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220102 </arg2>	0.9999805092811584
Based on these data , the traditional use of the drug in UTI appears to be justified .	<arg1> the traditional use of the drug in UTI </arg1> <rel> appears </rel> <arg2>  </arg2>	0.999789297580719
Based on these data , the traditional use of the drug in UTI appears to be justified .	<arg1> the traditional use of the drug in UTI </arg1> <rel> to be justified </rel> <arg2>  </arg2>	0.9975889921188354
This document id is 30220111 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220111 </arg2>	0.9999793171882629
4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue .	<arg1> CSE </arg1> <rel> transurethrally infected </rel> <arg2> with UPEC NU14 </arg2>	0.9976555109024048
4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue .	<arg1> 4- pretreatment of animals with CSE </arg1> <rel> significantly reduced </rel> <arg2> the bacterial load in bladder tissue </arg2>	0.9907691478729248
4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue .	<arg1> 7-day pretreatment of animals with CSE </arg1> <rel> significantly reduced </rel> <arg2> the bacterial load in bladder tissue </arg2>	0.9838297963142395
This document id is 30220121 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30220121 </arg2>	0.999980092048645
CSE is assessed as an antiadhesive extract for which the traditional use in phytotherapy for UTI is justified .	<arg1> CSE </arg1> <rel> is assessed </rel> <arg2> as an antiadhesive extract </arg2>	0.9999731779098511
CSE is assessed as an antiadhesive extract for which the traditional use in phytotherapy for UTI is justified .	<arg1> an antiadhesive extract </arg1> <rel> is justified </rel> <arg2> the traditional use in phytotherapy for UTI </arg2>	0.9417781233787537
This document id is 30230001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230001 </arg2>	0.9999781250953674
2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate product for the two step-synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant .	<arg1> 2- ( 4-Chlorophenyl ) -4-metathiazanone </arg1> <rel> is </rel> <arg2> the intermediate product for the two step-synthesis of chlormezanone ( </arg2>	0.7869299650192261
This document id is 30230002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230002 </arg2>	0.9999783635139465
2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate in the two-step synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant .	<arg1> 2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 </arg1> <rel> is </rel> <arg2> the intermediate in the two-step synthesis of chlormezanone ( </arg2>	0.9159649610519409
This document id is 30230011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230011 </arg2>	0.999980628490448
The second step includes the oxidation of its sulfur atom .	<arg1> The second step </arg1> <rel> includes </rel> <arg2> the oxidation of its sulfur atom </arg2>	0.999994158744812
This document id is 30230012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230012 </arg2>	0.999981164932251
The second step is the oxidation of the sulfur atom .	<arg1> The second step </arg1> <rel> is </rel> <arg2> the oxidation of the sulfur atom </arg2>	0.9999946355819702
This document id is 30230021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230021 </arg2>	0.9999800324440002
It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )	<arg1> methylamine </arg1> <rel> forming </rel> <arg2> the hemiaminale </arg2>	0.9996085166931152
It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )	<arg1> It </arg1> <rel> has been found </rel> <arg2>  </arg2>	0.8067184090614319
It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )	<arg1> the foregoing reaction of 4-chlorobenzaldehyde with methylamine </arg1> <rel> leads </rel> <arg2> to a remarkable better yield </arg2>	0.9821631908416748
It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )	<arg1> the subsequent addition of β-mercaptopropionic acid </arg1> <rel> leads </rel> <arg2> to a remarkable better yield </arg2>	0.9977360963821411
This document id is 30230022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230022 </arg2>	0.9999825954437256
This document id is 30230031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230031 </arg2>	0.9999821782112122
than the route via the hemimercaptale ( 42 % of th . ) .2 could be oxidized with sodium perborate superior to potassium permanganate .	<arg1> the route via ( 42 % of th . ) .2 </arg1> <rel> could be oxidized </rel> <arg2> with sodium perborate superior to potassium permanganate hemimercaptale </arg2>	0.7860463857650757
This document id is 30230032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230032 </arg2>	0.9999800324440002
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> of 2 </arg1> <rel> is obtained </rel> <arg2> when the half-aminal is first formed from 4-chlorobenzaldehyde , then acid </arg2>	0.8802890777587891
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> the half-aminal </arg1> <rel> is formed </rel> <arg2> from 4-chlorobenzaldehyde first </arg2>	0.9991268515586853
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> 4-chlorobenzaldehyde </arg1> <rel> reacts </rel> <arg2> with β-mercaptopropionic acid then </arg2>	0.9988248944282532
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> the reverse </arg1> <rel> is added </rel> <arg2>  </arg2>	0.9981878995895386
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> of 2 </arg1> <rel> is obtained </rel> <arg2> when the half-aminal is first formed from methylamine , which then reacts with β-mercaptopropionic acid </arg2>	0.9365967512130737
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> the half-aminal </arg1> <rel> is formed </rel> <arg2> from methylamine first </arg2>	0.9988107681274414
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> methylamine </arg1> <rel> reacts </rel> <arg2> with β-mercaptopropionic acid then </arg2>	0.9993168115615845
of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .	<arg1> the reverse </arg1> <rel> is added </rel> <arg2> via the half-mercaptal d.th </arg2>	0.3610149919986725
This document id is 30230041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230041 </arg2>	0.9999815225601196
The racemic chlormezanone ( 1 ) is resolved quickly on a gram scale by preparative column chromatography on a Chiralcel® OD column ( tris ( 3,5-dimethyl-phenyl-carbamoyl ) cellulose on silicagel ) .	<arg1> The racemic chlormezanone </arg1> <rel> is resolved quickly </rel> <arg2> on a gram scale by preparative column chromatography on a Chiralcel® OD column </arg2>	0.9993377923965454
This document id is 30230042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230042 </arg2>	0.9999800324440002
Sodium perborate is clearly superior to potassium permanganate as an oxidizing agent .	<arg1> Sodium perborate </arg1> <rel> is </rel> <arg2> clearly superior to potassium permanganate as an oxidizing agent </arg2>	0.9967359900474548
Sodium perborate is clearly superior to potassium permanganate as an oxidizing agent .	<arg1> Sodium perborate </arg1> <rel> to </rel> <arg2> potassium permanganate as an oxidizing agent </arg2>	0.5616239905357361
This document id is 30230051 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230051 </arg2>	0.9999802112579346
The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .	<arg1> The resolution </arg1> <rel> needed </rel> <arg2> only 40 min </arg2>	0.9998006820678711
The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .	<arg1> flow rate </arg1> <rel> are determined </rel> <arg2> prior with an analytical column </arg2>	0.84280925989151
The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .	<arg1> composition of the mobile phase </arg1> <rel> are determined </rel> <arg2> prior with an analytical column </arg2>	0.932162344455719
The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .	<arg1> temperature as the most important factors </arg1> <rel> are determined </rel> <arg2> prior with an analytical column </arg2>	0.9105442762374878
This document id is 30230052 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230052 </arg2>	0.9999778270721436
The racemic chloromezanone ( 1 ) can be separated rapidly in the grammaÞstab on a Chiralcel® OD column .	<arg1> The racemic chloromezanone </arg1> <rel> can be separated rapidly </rel> <arg2> in the grammaÞstab on a Chiralcel® column </arg2>	0.7521796226501465
This document id is 30230061 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230061 </arg2>	0.9999793767929077
Both dissociation constants could be determined for the first time with the aid of a log pKa-Titrator of the Sirius Co. , which needs for the registration of the curves only 15–17 min in the pH range of 2–12 .	<arg1> Both dissociation constants </arg1> <rel> could be determined </rel> <arg2> for the first time with the aid of a log pKa-Titrator of the Sirius Co. </arg2>	0.9990106821060181
Both dissociation constants could be determined for the first time with the aid of a log pKa-Titrator of the Sirius Co. , which needs for the registration of the curves only 15–17 min in the pH range of 2–12 .	<arg1> the Sirius Co. </arg1> <rel> needs </rel> <arg2> for the registration of the curves only </arg2>	0.6482467651367188
This document id is 30230062 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230062 </arg2>	0.9999797940254211
If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .	<arg1> the crucial factors such as flow rate </arg1> <rel> are determined </rel> <arg2> on analytical columns first </arg2>	0.9948530793190002
If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .	<arg1> the separation </arg1> <rel> requires </rel> <arg2> only 40 min then </arg2>	0.9991428852081299
If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .	<arg1> the crucial factors such as mobile phase composition </arg1> <rel> are determined </rel> <arg2> on analytical columns first </arg2>	0.9968646764755249
If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .	<arg1> the crucial factors such as temperature </arg1> <rel> are determined </rel> <arg2> on analytical columns first </arg2>	0.9974615573883057
This document id is 30230071 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230071 </arg2>	0.99997878074646
This speed outplayed the disturbing cleavage of the S-C bond of chlormezanone at strong acidic and alkaline pH values .	<arg1> This speed </arg1> <rel> outplayed </rel> <arg2> the disturbing cleavage of the S-C bond of chlormezanone at strong acidic pH values </arg2>	0.8409647941589355
This speed outplayed the disturbing cleavage of the S-C bond of chlormezanone at strong acidic and alkaline pH values .	<arg1> This speed </arg1> <rel> outplayed </rel> <arg2> the disturbing cleavage of the S-C bond of chlormezanone at strong alkaline pH values </arg2>	0.7827147245407104
This document id is 30230072 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230072 </arg2>	0.9999790787696838
For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 .	<arg1> the two dissociation constants of 1 </arg1> <rel> could be determined </rel> <arg2> For the first time </arg2>	0.8947164416313171
For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 .	<arg1> the log pKa titrator from Sirius Co. </arg1> <rel> requires </rel> <arg2> only 15-17 min to register the titration curves in the pH range 2-12 </arg2>	0.9909180402755737
For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 .	<arg1> only 15-17 min </arg1> <rel> to register </rel> <arg2> the titration curves in the pH range 2-12 </arg2>	0.29307642579078674
This document id is 30230082 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30230082 </arg2>	0.9999551773071289
This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .	<arg1> This speed </arg1> <rel> glosses </rel> <arg2> over the interfering break in the S-C bond of 1 in the strongly acidic pH ranges </arg2>	0.960203230381012
This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .	<arg1> the interfering break in the S-C bond of 1 in the strongly acidic pH </arg1> <rel> ranges </rel> <arg2>  </arg2>	0.8100334405899048
This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .	<arg1> the interfering break in the S-C bond of 1 in the strongly alkaline pH </arg1> <rel> ranges </rel> <arg2>  </arg2>	0.8808305263519287
This document id is 30240001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240001 </arg2>	0.9999483823776245
Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .	<arg1> an antiseptic wound powder </arg1> <rel> based </rel> <arg2> on the antibiotic tyrothricin </arg2>	0.9998555183410645
Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .	<arg1> The efficacy of an antiseptic wound powder </arg1> <rel> was investigated </rel> <arg2> in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions </arg2>	0.9998098611831665
Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .	<arg1> The efficacy of an antiseptic wound powder </arg1> <rel> was investigated </rel> <arg2> in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions </arg2>	0.9998084306716919
Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .	<arg1> The tolerance of an antiseptic wound powder </arg1> <rel> was investigated </rel> <arg2> in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions </arg2>	0.999845027923584
Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .	<arg1> The tolerance of an antiseptic wound powder </arg1> <rel> was investigated </rel> <arg2> in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions </arg2>	0.9998393058776855
This document id is 30240002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240002 </arg2>	0.9999471306800842
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> an antibiotic wound powder </arg1> <rel> containing </rel> <arg2> the active ingredient tyrothricin </arg2>	0.9998214244842529
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the efficacy of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in posttraumatic skin lesions In a prospective , randomized multicenter study </arg2>	0.999492347240448
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the efficacy of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in postoperative skin lesions In a prospective , randomized multicenter study </arg2>	0.9994942545890808
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the tolerability of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in posttraumatic skin lesions In a prospective , randomized multicenter study </arg2>	0.9978013038635254
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the tolerability of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in postoperative skin lesions In a prospective , randomized multicenter study </arg2>	0.9976646900177002
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> an antibiotic wound powder </arg1> <rel> containing </rel> <arg2> the active ingredient tyrothricin randomized </arg2>	0.9864463806152344
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the efficacy of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in posttraumatic skin lesions Purpose In a prospective , randomized multicenter study </arg2>	0.13561350107192993
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the efficacy of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in postoperative skin lesions Purpose In a prospective , randomized multicenter study </arg2>	0.12850290536880493
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the tolerability of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in posttraumatic skin lesions Purpose In a prospective , randomized multicenter study </arg2>	0.9604375958442688
Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .	<arg1> the tolerability of an antibiotic wound powder </arg1> <rel> were investigated </rel> <arg2> in postoperative skin lesions Purpose In a prospective , randomized multicenter study </arg2>	0.9570220112800598
This document id is 30240011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240011 </arg2>	0.9999558329582214
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 male patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with posttraumatic cutaneous lesions with infection In 5 centers </arg2>	0.9873830080032349
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> Patients area </arg1> <rel> ≥ </rel> <arg2> 200 mm2 </arg2>	0.9545882940292358
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 male patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with posttraumatic cutaneous lesions in danger of infection In 5 centers </arg2>	0.9839274883270264
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 male patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions with infection In 5 centers </arg2>	0.9851953983306885
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 male patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions in danger of infection In 5 centers </arg2>	0.9854486584663391
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with posttraumatic cutaneous lesions with infection In 5 centers </arg2>	0.9865836501121521
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with posttraumatic cutaneous lesions in danger of infection In 5 centers </arg2>	0.9831258654594421
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions with infection In 5 centers </arg2>	0.98466956615448
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions in danger of infection In 5 centers </arg2>	0.9850988388061523
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> area </arg1> <rel> ≥ </rel> <arg2> 200 mm2 </arg2>	0.9867694973945618
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 male patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with posttraumatic cutaneous lesions in danger of infection In 5 centers </arg2>	0.990778386592865
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> area </arg1> <rel> ≥ </rel> <arg2> 200 mm2 </arg2>	0.9763196706771851
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 male patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions with infection area In 5 centers </arg2>	0.9407992959022522
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 male patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions in danger of infection In 5 centers </arg2>	0.9909960627555847
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with posttraumatic cutaneous lesions with infection In 5 centers </arg2>	0.9894037842750549
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with posttraumatic cutaneous lesions in danger of infection In 5 centers </arg2>	0.9913902878761292
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions with infection area In 5 centers </arg2>	0.9408683180809021
Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .	<arg1> 131 female patients from 18–85 years </arg1> <rel> were included </rel> <arg2> with surgical cutaneous lesions in danger of infection In 5 centers </arg2>	0.9918413162231445
This document id is 30240012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240012 </arg2>	0.9999666810035706
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 men </arg1> <rel> aged </rel> <arg2> 18 to 85 years with a posttraumatic/postoperative infected skin </arg2>	0.8892615437507629
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 men aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ) </arg1> <rel> participated </rel> <arg2> In 5 study sites </arg2>	0.9085909724235535
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 men </arg1> <rel> aged </rel> <arg2> 18 to 85 years with a infection-prone skin lesion </arg2>	0.9660121202468872
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 men aged 18 to 85 years with a infection-prone skin lesion ( wound </arg1> <rel> ≥ participated </rel> <arg2> In 5 study sites area 200 mm2 ) </arg2>	0.6168845891952515
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 men aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 ) </arg1> <rel> participated </rel> <arg2> In 5 study sites </arg2>	0.2970832884311676
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 women </arg1> <rel> aged </rel> <arg2> 18 to 85 years with </arg2>	0.9666498303413391
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 women aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ) </arg1> <rel> participated </rel> <arg2> In 5 study sites </arg2>	0.9082245826721191
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 women </arg1> <rel> aged </rel> <arg2> 18 to 85 years with a infection-prone skin lesion </arg2>	0.9312223196029663
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 women aged 18 to 85 years with a infection-prone skin lesion ( wound area </arg1> <rel> ≥ participated </rel> <arg2> In 5 study sites 200 mm2 ) </arg2>	0.6044005751609802
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 women aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 ) </arg1> <rel> participated </rel> <arg2> In 5 study sites </arg2>	0.22969138622283936
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 men </arg1> <rel> aged </rel> <arg2> 18 to 85 years with a infected </arg2>	0.9173087477684021
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> METHODS 131 men aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ) </arg1> <rel> participated </rel> <arg2> In 5 study sites </arg2>	0.8207695484161377
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> METHODS 131 men aged 18 to 85 years with a infection-prone skin lesion ( </arg1> <rel> ≥ participated </rel> <arg2> 5 study sites wound area 200 mm2 ) In </arg2>	0.5201905965805054
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 men aged 18 to 85 years with a infection-prone skin lesion ( wound area 200 mm2 </arg1> <rel> participated </rel> <arg2> In 5 study sites </arg2>	0.25854673981666565
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> 131 women </arg1> <rel> aged </rel> <arg2> 18 to 85 years </arg2>	0.9799456000328064
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> METHODS 131 women aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ) </arg1> <rel> participated </rel> <arg2> In 5 study sites </arg2>	0.8236483335494995
PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .	<arg1> METHODS 131 women aged 18 to 85 years with a infection-prone skin lesion ( wound </arg1> <rel> ≥ participated </rel> <arg2> 5 study sites area 200 mm2 ) In </arg2>	0.08757250756025314
This document id is 30240021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240021 </arg2>	0.9999601244926453
In a double-blind study , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g of vehicle ) or placebo powder ( n = 69 ) was applied to the wound twice daily for 9 days .	<arg1> tyrothricin 0.1 g tyrothricin per 100 g of vehicle </arg1> <rel> was applied </rel> <arg2> to the wound In a double-blind study twice daily for 9 days </arg2>	0.4772789180278778
In a double-blind study , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g of vehicle ) or placebo powder ( n = 69 ) was applied to the wound twice daily for 9 days .	<arg1> placebo powder </arg1> <rel> was applied </rel> <arg2> to the wound In a double-blind study twice daily for 9 days </arg2>	0.7972113490104675
This document id is 30240022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240022 </arg2>	0.999965488910675
During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .	<arg1> tyrothricin 0.1 g tyrothricin per 100 g base </arg1> <rel> was </rel> <arg2> to be applied to the wound area 2 × daily During 9 days of double-blind treatment </arg2>	0.7654988765716553
During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .	<arg1> tyrothricin 0.1 g tyrothricin per 100 g base </arg1> <rel> to be applied </rel> <arg2> to the wound area 2 daily </arg2>	0.5963430404663086
During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .	<arg1> placebo powder </arg1> <rel> was </rel> <arg2> to be applied to the wound area 2 × daily During 9 days of double-blind treatment </arg2>	0.8515183925628662
During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .	<arg1> placebo powder </arg1> <rel> to be applied × </rel> <arg2> to the wound area 2 daily </arg2>	0.14400354027748108
This document id is 30240031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240031 </arg2>	0.9999682903289795
The primary aim was to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment ( α = 0.025 ; one-sided ) .	<arg1> The primary aim </arg1> <rel> was </rel> <arg2> to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment ( </arg2>	0.9051077961921692
This document id is 30240032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240032 </arg2>	0.9999648332595825
The primary efficacy parameter was the average daily reduction in wound radius calculated from wound area between the start and end of randomized treatment ( α = 0.025 ; unilateral ) .	<arg1> The primary efficacy parameter </arg1> <rel> was </rel> <arg2> the average daily reduction in wound radius </arg2>	0.9999653100967407
The primary efficacy parameter was the average daily reduction in wound radius calculated from wound area between the start and end of randomized treatment ( α = 0.025 ; unilateral ) .	<arg1> wound radius </arg1> <rel> calculated </rel> <arg2> from wound area between the start and end of randomized treatment ( α = 0.025 </arg2>	0.9376172423362732
This document id is 30240041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240041 </arg2>	0.9999669790267944
Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .	<arg1> a wound index </arg1> <rel> was calculated </rel> <arg2> from the assessments of rubor </arg2>	0.9982962012290955
Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .	<arg1> a wound index </arg1> <rel> was calculated </rel> <arg2> from the assessments of crusting </arg2>	0.9980909824371338
Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .	<arg1> a wound index </arg1> <rel> was calculated </rel> <arg2> from the assessments of exudation </arg2>	0.9982283115386963
Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .	<arg1> a wound index </arg1> <rel> was calculated </rel> <arg2> from the assessments of pain </arg2>	0.9982321858406067
Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .	<arg1> a wound index </arg1> <rel> was calculated </rel> <arg2> from the assessments of functional impairment </arg2>	0.9981563091278076
This document id is 30240042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240042 </arg2>	0.9999709725379944
A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .	<arg1> A wound index </arg1> <rel> was calculated </rel> <arg2> from the assessment of symptoms of redness </arg2>	0.9995662569999695
A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .	<arg1> A wound index </arg1> <rel> was calculated </rel> <arg2> from the assessment of symptoms of coatings </arg2>	0.9995830059051514
A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .	<arg1> A wound index </arg1> <rel> was calculated </rel> <arg2> from the assessment of symptoms of exudation </arg2>	0.9995841383934021
A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .	<arg1> A wound index </arg1> <rel> was calculated </rel> <arg2> from the assessment of symptoms of pain </arg2>	0.999584436416626
A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .	<arg1> A wound index </arg1> <rel> was calculated </rel> <arg2> from the assessment of symptoms of functional limitation </arg2>	0.9996183514595032
This document id is 30240051 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240051 </arg2>	0.9999731779098511
Results : The treatment groups were comparable at baseline .	<arg1> The treatment groups </arg1> <rel> were </rel> <arg2> comparable at baseline </arg2>	0.9999113082885742
This document id is 30240052 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240052 </arg2>	0.9999678730964661
Results : Wound radius decreased by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the intention-to-treat collective at comparable baseline ( p = 0.016 ; one-sided ) .	<arg1> Wound radius </arg1> <rel> decreased </rel> <arg2> by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the collective at comparable baseline intention-to-treat </arg2>	0.07453037053346634
This document id is 30240061 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240061 </arg2>	0.9999721646308899
During randomized treatment , the radius of the lesions was reduced at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for placebo ( p = 0.016 ; one-sided ; intention-to-treat data set ) .	<arg1> the radius of the lesions </arg1> <rel> was reduced </rel> <arg2> at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for During randomized treatment </arg2>	0.5909424424171448
During randomized treatment , the radius of the lesions was reduced at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for placebo ( p = 0.016 ; one-sided ; intention-to-treat data set ) .	<arg1> one-sided intention-to-treat data </arg1> <rel> set </rel> <arg2>  </arg2>	0.8033376932144165
This document id is 30240062 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240062 </arg2>	0.9999725818634033
The wound index decreased by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo ( p = 0.0048 ; one-sided ) .	<arg1> The wound index </arg1> <rel> decreased </rel> <arg2> by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo </arg2>	0.999602735042572
This document id is 30240071 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240071 </arg2>	0.9999703168869019
The wound index decreased at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin and placebo , respectively ( p = 0.0048 ; one-sided ) .	<arg1> The wound index </arg1> <rel> decreased respectively </rel> <arg2> at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin , </arg2>	0.9645310044288635
The wound index decreased at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin and placebo , respectively ( p = 0.0048 ; one-sided ) .	<arg1> The wound index </arg1> <rel> decreased respectively </rel> <arg2> at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for placebo , </arg2>	0.9766157865524292
This document id is 30240072 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240072 </arg2>	0.9999701380729675
Of 4 adverse events in each of the two treatment groups , a causal relationship with the medication could not be ruled out in only 3 cases under placebo .	<arg1> a causal relationship with the medication </arg1> <rel> could not be ruled out </rel> <arg2> in only 3 cases under placebo </arg2>	0.9992918968200684
This document id is 30240081 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240081 </arg2>	0.9999696016311646
4 adverse events occurred in each group .	<arg1> 4 adverse events </arg1> <rel> occurred </rel> <arg2> in each group </arg2>	0.9999780654907227
This document id is 30240082 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240082 </arg2>	0.9999691247940063
Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .	<arg1> The results </arg1> <rel> demonstrate </rel> <arg2> its superiority over placebo </arg2>	0.9999698996543884
Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .	<arg1> The results </arg1> <rel> demonstrate </rel> <arg2> the promotion of healing of infected skin lesions by Tyrothricin powder </arg2>	0.999947726726532
Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .	<arg1> The results </arg1> <rel> demonstrate </rel> <arg2> the promotion of healing of infection-prone skin lesions by Tyrothricin powder </arg2>	0.9999327063560486
This document id is 30240091 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240091 </arg2>	0.9999712109565735
A causal relationship with the investigational drug could not be excluded in 3 of the placebo group .	<arg1> A causal relationship with the investigational drug </arg1> <rel> could not be excluded </rel> <arg2> in 3 of the placebo group </arg2>	0.9999398589134216
This document id is 30240092 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240092 </arg2>	0.9999688863754272
Due to the good tolerability and the lack of a systemic effect , the substance is suitable for therapy in skin injuries .	<arg1> the substance </arg1> <rel> is </rel> <arg2> suitable for therapy in skin injuries </arg2>	0.9999542832374573
This document id is 30240101 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240101 </arg2>	0.9999784827232361
Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .	<arg1> The results </arg1> <rel> confirm </rel> <arg2> the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection </arg2>	0.9760427474975586
Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .	<arg1> The results </arg1> <rel> confirm </rel> <arg2> the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of danger of infection </arg2>	0.9215868711471558
This document id is 30240111 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240111 </arg2>	0.9999805092811584
A superior efficacy compared to placebo was demonstrated .	<arg1> A superior efficacy </arg1> <rel> compared </rel> <arg2> to placebo </arg2>	0.9998107552528381
A superior efficacy compared to placebo was demonstrated .	<arg1> A superior efficacy compared to placebo </arg1> <rel> was demonstrated </rel> <arg2>  </arg2>	0.9969838261604309
This document id is 30240121 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30240121 </arg2>	0.9999802112579346
Due to its good tolerability and the absence of a systemic effects tyrothricin powder is appropriate for the treatment of superficial skin lesions .	<arg1> tolerability tyrothricin powder </arg1> <rel> is </rel> <arg2> appropriate for the treatment of superficial skin lesions </arg2>	0.9885562062263489
Due to its good tolerability and the absence of a systemic effects tyrothricin powder is appropriate for the treatment of superficial skin lesions .	<arg1> the absence of a systemic effects tyrothricin powder </arg1> <rel> is </rel> <arg2> appropriate for the treatment of superficial skin lesions </arg2>	0.1912301480770111
This document id is 30250001 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250001 </arg2>	0.999986469745636
2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted with aromatic amines selectively by substitution at the 5-position to yield the amidines 2 .	<arg1> 2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine </arg1> <rel> reacted selectively </rel> <arg2> with aromatic amines by substitution at the 5-position </arg2>	0.7636792063713074
This document id is 30250002 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250002 </arg2>	0.9999832510948181
2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted selectively with aromatic amines with substitution at the 5-position to give the amidines 2 .	<arg1> 2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine </arg1> <rel> reacted selectively </rel> <arg2> with aromatic amines with substitution at the 5-position </arg2>	0.983757495880127
This document id is 30250011 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250011 </arg2>	0.9999836683273315
The 4-aminophenol 2c could also be synthesized by cleavage of the ether 2b .	<arg1> The 4-aminophenol 2c </arg1> <rel> could also be synthesized </rel> <arg2> by cleavage of the ether 2b </arg2>	0.9950242638587952
This document id is 30250012 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250012 </arg2>	0.9999858140945435
The 4-aminophenol 2c could also be prepared by ether cleavage of 2b .	<arg1> The 4-aminophenol 2c </arg1> <rel> could also be prepared </rel> <arg2> by ether cleavage of 2b </arg2>	0.9957804679870605
This document id is 30250021 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250021 </arg2>	0.9999830722808838
The structure of 2c was proved by X-ray crystal analysis .	<arg1> The structure of 2c </arg1> <rel> was proved </rel> <arg2> by X-ray crystal analysis </arg2>	0.9999806880950928
This document id is 30250022 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250022 </arg2>	0.999984860420227
This document id is 30250031 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250031 </arg2>	0.9999860525131226
Aminomethylation of 2c yielded the amodiaquine analogue 3 .	<arg1> Aminomethylation of 2c </arg1> <rel> yielded </rel> <arg2> the amodiaquine analogue 3 </arg2>	0.9998779296875
This document id is 30250032 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250032 </arg2>	0.9999866485595703
Aminomethylation of 2c afforded the amodiaquine analogue 3 .	<arg1> Aminomethylation of 2c </arg1> <rel> afforded </rel> <arg2> the amodiaquine analogue 3 </arg2>	0.9993507862091064
This document id is 30250041 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250041 </arg2>	0.9999845623970032
The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .	<arg1> The mono- derivatives 4 </arg1> <rel> were obtained </rel> <arg2> by reaction of compound 1 with phenol Mannich base hydrochlorides </arg2>	0.9993550181388855
The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .	<arg1> The mono- derivatives 5 </arg1> <rel> were obtained </rel> <arg2> by reaction of compound 1 with phenol Mannich base hydrochlorides </arg2>	0.9962236285209656
The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .	<arg1> The bisaminomethylated derivatives 4 </arg1> <rel> were obtained </rel> <arg2> by reaction of compound 1 with phenol Mannich base hydrochlorides </arg2>	0.9978642463684082
The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .	<arg1> The bisaminomethylated derivatives 5 </arg1> <rel> were obtained </rel> <arg2> by reaction of compound 1 with phenol Mannich base hydrochlorides </arg2>	0.9942943453788757
This document id is 30250042 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250042 </arg2>	0.9999855756759644
Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .	<arg1> Reaction of 1 with phenol Mannich base hydrochlorides </arg1> <rel> gave </rel> <arg2> the mono- derivatives 4 </arg2>	0.9965460300445557
Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .	<arg1> Reaction of 1 with phenol Mannich base hydrochlorides </arg1> <rel> gave </rel> <arg2> the mono- derivatives 5 </arg2>	0.9963699579238892
Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .	<arg1> Reaction of 1 with phenol Mannich base hydrochlorides </arg1> <rel> gave </rel> <arg2> the bisaminomethylated derivatives 4 </arg2>	0.9925751686096191
Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .	<arg1> Reaction of 1 with phenol Mannich base hydrochlorides </arg1> <rel> gave </rel> <arg2> the bisaminomethylated derivatives 5 </arg2>	0.9891566038131714
This document id is 30250051 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250051 </arg2>	0.9999554753303528
Compounds 3–5 were tested in vitro for antimalarial activity using chloroquine-sensitive and resistant Plasmodium-falciparum strains .	<arg1> Compounds 3–5 </arg1> <rel> were tested </rel> <arg2> in vitro for antimalarial activity </arg2>	0.9751692414283752
This document id is 30250052 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250052 </arg2>	0.9999483227729797
Compounds 3-5 were tested for activity against malaria with a chloroquine-sensitive and -resistant Plasmodium falciparum strain in vitro .	<arg1> Compounds 3-5 </arg1> <rel> were tested </rel> <arg2> for activity against malaria with a chloroquine-sensitive Plasmodium falciparum strain in vitro </arg2>	0.9936553239822388
Compounds 3-5 were tested for activity against malaria with a chloroquine-sensitive and -resistant Plasmodium falciparum strain in vitro .	<arg1> Compounds 3-5 </arg1> <rel> were tested </rel> <arg2> for activity against malaria with a -resistant Plasmodium falciparum strain in vitro </arg2>	0.9951198697090149
This document id is 30250061 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250061 </arg2>	0.9999539852142334
The highest activities were shown by the pyronaridine-type compounds 5a and 5b with IC50 values of approximately 200 nM .	<arg1> The highest activities </arg1> <rel> were shown </rel> <arg2> by the pyronaridine-type compounds 5a with IC50 </arg2>	0.8566272854804993
The highest activities were shown by the pyronaridine-type compounds 5a and 5b with IC50 values of approximately 200 nM .	<arg1> The highest activities </arg1> <rel> were shown </rel> <arg2> by the pyronaridine-type compounds 5b IC50 </arg2>	0.9109514951705933
This document id is 30250062 .	<arg1> This document id </arg1> <rel> is </rel> <arg2> 30250062 </arg2>	0.999954104423523
Pyronaridine analogues 5a and 5b showed the best activities with IC50 values around 200 nM .	<arg1> Pyronaridine analogues 5a </arg1> <rel> showed </rel> <arg2> the best activities with IC50 values around 200 nM </arg2>	0.9759506583213806
Pyronaridine analogues 5a and 5b showed the best activities with IC50 values around 200 nM .	<arg1> Pyronaridine analogues 5b </arg1> <rel> showed </rel> <arg2> the best activities with IC50 values around 200 nM </arg2>	0.9820564389228821
